Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases
Journal of Biochemical and Molecular Toxicology · 2026-08 · 40 (8)
DOI: 10.1002/jbt.71033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 27.07.2026. Verfasst von Peiyun Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Hengyang Medical School, University of South China, Hengyang, Hunan, China. Hauptthemen laut MEDLINE: Lipid Metabolism, Cardiovascular Diseases, Myocardium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, Hunan Province College Students' Innovation Training Program Project.
Abstract (Originalsprache)
Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation (FAO) supplying the majority of ATP in the healthy adult heart. This review synthesizes the core regulatory network governing cardiac lipid metabolism, encompassing lipid droplet dynamics mediated by perilipins (e.g., Plin5, Plin2), fatty acid uptake via CD36, systemic lipid modulation by apolipoproteins (e.g., APOC3), and the central energy‐sensing AMPK/PGC‐1α/PPARα axis. Dysregulation of this network initiates a self‐perpetuating lipotoxic cycle, characterized by the accumulation of toxic lipid intermediates (e.g., diacylglycerols, ceramides), oxidative stress, and inflammatory activation, which serves as a common pathological mechanism across diverse cardiovascular diseases (CVDs), including atherosclerosis, heart failure, diabetic cardiomyopathy, and ischemic injury. Emerging from this mechanistic understanding is a promising landscape of biomarkers—such as specific ceramide species, the ApoB/ApoA‐1 ratio, and circulating perilipins—and targeted therapeutic strategies, including APOC3 inhibitors, SGLT2 inhibitors, and Plin5‐directed therapies. Future advances will depend on integrating multi‐omics technologies and precision medicine approaches to tailor interventions to specific metabolic phenotypes, thereby opening new avenues for the prevention and treatment of CVDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
ORCID-Profile: Qun Zeng
Förderung
- Natural Science Foundation of Hunan Province
- Hunan Province College Students' Innovation Training Program Project
Zitieren
APA
Xie, P., Zeng, Q., Wang, H., & She, M. (2026). Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases. Journal of Biochemical and Molecular Toxicology, 40(8). https://doi.org/10.1002/jbt.71033
Vancouver
Xie P, Zeng Q, Wang H, She M. Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases. Journal of Biochemical and Molecular Toxicology. 2026;40(8). doi:10.1002/jbt.71033
BibTeX
@article{Xie2026,
author = {Xie, Peiyun and Zeng, Qun and Wang, Hongrui and She, Meihua},
title = {Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {8},
doi = {10.1002/jbt.71033}
}
EUVIMED